Trials / Completed
CompletedNCT05107063
An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes
A Multi-center, Prospective Observational Study to Investigate the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,972 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study investigated the effectiveness of pravastatin on renal function in Korean dyslipidemic patients with Type 2 diabetes.
Detailed description
This survey study investigated the effect of routine initiation single dose of pravastatin (10 mg, 20 mg, or 40 mg) on renal function in Korean dyslipidemic patients with Type 2 diabetes. The study also examined the effect of pravastatin on lipid profiles, glucose metabolism, and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pravastatin | Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily. |
Timeline
- Start date
- 2016-01-20
- Primary completion
- 2018-04-19
- Completion
- 2018-04-19
- First posted
- 2021-11-04
- Last updated
- 2021-11-04
Locations
47 sites across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05107063. Inclusion in this directory is not an endorsement.